What Entrada Therapeutics does

Entrada Therapeutics is a clinical-stage biopharmaceutical company founded in 2016-2017 and headquartered in Boston, Massachusetts, that develops intracellular therapeutics built on its proprietary Endosomal Escape Vehicle (EEV™) Platform — a library of cyclic cell-penetrating peptides designed to enable efficient intracellular delivery of oligonucleotides, proteins, and other therapeutic modalities into tissues previously considered inaccessible and undruggable. Preclinical data on file indicates approximately half of EEV-therapeutics reach their intended intracellular target, compared with only ~1-2% for conventional biological therapeutics, and the platform has demonstrated near-complete dystrophin restoration in skeletal muscle in Duchenne muscular dystrophy (DMD) preclinical models.

The company's clinical pipeline focuses on neuromuscular and inherited retinal diseases, led by four EEV-Oligonucleotide candidates for exon 44, 45, 50, and 51 skip-amenable Duchenne muscular dystrophy (ENTR-601-44, -45, -50, -51), of which ENTR-601-44 and ENTR-601-45 are in Phase 1/2 (ELEVATE-44-201 and ELEVATE-45-201) studies across the U.S., U.K., and EU. The myotonic dystrophy type 1 (DM1) program VX-670 (formerly ENTR-701) is out-licensed to Vertex Pharmaceuticals, which holds global development, manufacturing, and commercialization rights; Entrada also has discovery-stage ENTR-801 targeting USH2A for inherited retinal diseases. The company is publicly traded on NASDAQ under ticker TRDA with a market capitalization of approximately $531M as of April 2026, 86.39% institutional ownership, $254.9M cash and marketable securities (March 31, 2026), and a disclosed runway into Q3 2027.

Entrada's revenue model is currently driven entirely by collaboration revenue from the December 2022 Vertex Pharmaceuticals agreement, which delivered $224M upfront, $26M equity investment, and up to $485M in potential milestones. Q1 2026 collaboration revenue was $0.9M versus $20.6M in Q1 2025, reflecting milestone-driven lumpiness, and the company is pre-commercial with no approved products. Operating losses are widening (Q1 2026 net loss of $39.7M) as the company invests in multiple clinical readouts. The May 7, 2026 ELEVATE-44-201 Cohort 1 readout showing only a 2.36% dystrophin increase triggered a 57.27% one-day stock decline to $6.85/share and multiple securities-fraud investigations by Pomerantz, Schall, and Holzer & Holzer, materially elevating both clinical-program and litigation risk for the franchise.

Name

Entrada Therapeutics

Legal name

Entrada Therapeutics, Inc.

Website

https://entradatx.com

Company type

Public

Founded year

2017

Operating status

Operating

Headcount range

101–250 employees

Short description

Entrada Therapeutics is a Boston-based, NASDAQ-listed clinical-stage biopharmaceutical company developing intracellular therapeutics for Duchenne muscular dystrophy, myotonic dystrophy type 1, and inherited retinal diseases using its proprietary cyclic cell-penetrating peptide EEV™ Platform.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Blood and Organ Banks (621991)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Gene Therapy Regulatory, Pharmacovigilance & Clinical Operations Services (HLAAACAM)

akta.pro secondary industries

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery) (HLAAACAL)

Keywords

• Intracellular therapeutics
• Cell-penetrating peptides
• Duchenne muscular dystrophy
• Myotonic dystrophy treatment
• Rare disease therapeutics

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Collaboration Revenue: Revenue recognized under the strategic collaboration and license agreement with Vertex Pharmaceuticals for the development of EEV-therapeutics for myotonic dystrophy type 1 (DM1), including VX-670 and additional DM1-related research. Q1 2026 collaboration revenue was $0.9 million versus $20.6 million in Q1 2025. Entrada received $224 million upfront and a $26 million equity investment, with potential for up to $485 million in milestone payments.
2. Future Product Sales (Pipeline, Pre-Commercial): Entrada is a clinical-stage biopharmaceutical company with no approved commercial products. Future revenue is expected to derive from commercialization of EEV-therapeutic product candidates for Duchenne muscular dystrophy (ENTR-601-44, -45, -50, -51), myotonic dystrophy type 1 (VX-670 with Vertex), and inherited retinal diseases (ENTR-801: USH2A and undisclosed programs).

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Core offering

Entrada Therapeutics is a clinical-stage biopharmaceutical company developing intracellular therapeutics built on its proprietary Endosomal Escape Vehicle (EEV™) Platform — a library of cyclic cell-penetrating peptides engineered to deliver oligonucleotides and other therapeutic modalities into cells while escaping endosomal clearance. Its pipeline spans clinical-stage product candidates for Duchenne muscular dystrophy (ENTR-601-44, ENTR-601-45, ENTR-601-50, ENTR-601-51), the Vertex-partnered DM1 program VX-670/ENTR-701, and a discovery-stage program ENTR-801 for USH2A-related inherited retinal diseases.

Product overview

Entrada Therapeutics is a clinical-stage biopharmaceutical company built around a single unifying core technology — its proprietary Endosomal Escape Vehicle (EEV™) Platform — from which a modular portfolio of intracellular therapeutic product candidates is generated. The EEV™ Platform (cyclic cell-penetrating peptides) supports clinical-stage product candidates ENTR-601-44 and ENTR-601-45 in exon 44- and exon 45-skip amenable Duchenne muscular dystrophy (DMD), earlier-stage DMD candidates ENTR-601-50 and ENTR-601-51, the Vertex-partnered DM1 program VX-670 (formerly ENTR-701), and discovery-stage ENTR-801 for USH2A inherited retinal disease. Around these therapeutics, Entrada also operates the DREAMS Grant Program, a corporate-giving initiative that funds Duchenne-focused non-profits. The platform-plus-modular-candidates architecture means every named therapeutic leverages the same EEV delivery system while targeting different intracellular disease drivers.

Differentiator

Problem solved

Functional benefit

Brands

• EEV (Endosomal Escape Vehicle): Proprietary therapeutic platform of cyclic cell-penetrating peptides used to deliver oligonucleotides and other modalities intracellularly.
• DREAMS Grant Program

Products and services

• EEV™ Platform Proprietary Endosomal Escape Vehicle (EEV) Platform — a library of cyclic cell-penetrating peptides designed to enable efficient intracellular delivery of therapeutic modalities (oligonucleotides, proteins) into a wide range of organs, tissues and cells, engaging disease-causing targets previously considered inaccessible and undruggable.
• ENTR-601-44 EEV-Oligonucleotide therapeutic candidate for exon 44 skip-amenable Duchenne muscular dystrophy; being evaluated in the Phase 1/2 ELEVATE-44-201 study. Designed to address the underlying genetic cause of Duchenne to allow muscle cells to produce functional dystrophin.
• ENTR-601-45 EEV-Oligonucleotide therapeutic candidate for exon 45 skip-amenable Duchenne muscular dystrophy; being evaluated in the Phase 1/2 ELEVATE-45-201 study. DMC recommended Cohort 2 initiation at 10 mg/kg in June 2026.
• ENTR-601-50 EEV-Oligonucleotide therapeutic candidate for exon 50 skip-amenable Duchenne muscular dystrophy; preclinical-stage with efficacy data presented at OTS 2025 and World Muscle Society 2025.
• ENTR-601-51 EEV-Oligonucleotide therapeutic candidate for exon 51 skip-amenable Duchenne muscular dystrophy; preclinical-stage with efficacy poster presented at MDA Clinical & Scientific Conference 2026.
• VX-670 (ENTR-701) EEV-Oligonucleotide therapeutic candidate for myotonic dystrophy type 1 (DM1); being developed under a global collaboration with Vertex Pharmaceuticals, which is responsible for global development, manufacturing and commercialization. Currently in global Phase 1/2 clinical development.
• ENTR-801 Discovery-stage program targeting USH2A for inherited retinal diseases, built on the EEV Platform.

Quantifiable outcome

• ~50% of EEV-therapeutics reach intended intracellular target vs ~1-2% of conventional biological therapeutics (preclinical)
• +3 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature5 records

Partnerships

Twelve partnerships are on record, tiered flagship and minor.

• Vertex PharmaceuticalsflagshipStrategic or Co-development Partner · 8 December 2022Global collaboration to develop Endosomal Escape Vehicle (EEV) therapeutics for myotonic dystrophy type 1 (DM1), including Entrada's lead candidate ENTR-701/VX-670. Entrada received $224 million upfront, $26 million equity investment, and is eligible for up to $485 million in milestone payments. Vertex is responsible for global development, manufacturing, and commercialization. The four-year research collaboration has Entrada advancing certain research activities related to VX-670 and additional DM1-related research. Program is in global Phase 1/2 development with enrollment and dosing underway.
• Jett FoundationminorGTM or Marketing Partner2025 DREAMS Grant recipient — U.S.-based nonprofit headquartered in Massachusetts serving individuals affected by Duchenne muscular dystrophy. Grant funds Camp Promise year-round no-cost program for individuals aged 18+ living with Duchenne and other neuromuscular disorders.
• Parent Project apsminorGTM or Marketing Partner2025 DREAMS Grant recipient — Italian nonprofit supporting individuals with Duchenne and Becker muscular dystrophy. Grant funds home-based care and teleconsultation services for families in underserved regions of Southern Italy.
• CureDuchenneminorGTM or Marketing Partner2024 DREAMS Grant recipient supporting the CureDuchenne International Outreach Program to expand awareness, diagnosis, treatment and support for individuals affected by Duchenne in Nepal, Uganda, China and other countries throughout 2024-2025.
• The Little Hercules Walking Strong Foundation (LHF)minorGTM or Marketing Partner2024 DREAMS Grant recipient supporting individualized case management services for the Duchenne community and subsidizing the cost of translation services for families whose first language is not English.
• Walking StrongminorGTM or Marketing Partner2024 DREAMS Grant recipient expanding one-on-one mental wellness and life coaching, access to mobility and assistive devices, and canine support animals for individuals affected by Duchenne.
• The Akari FoundationminorGTM or Marketing Partner2023 DREAMS Grant recipient — Hispanic-focused nonprofit educating and empowering the Hispanic community about rare diseases with a focus on Duchenne, providing resources, awareness, advocacy and education entirely in Spanish.
• Neurology and Neuromuscular Care CenterminorGTM or Marketing Partner2023 DREAMS Grant recipient — nonprofit private practice led by Dr. Diana Castro providing care to neuromuscular patients from minority backgrounds who are underserved, uninsured or underinsured; grant funds hiring of first mental health professional.
• Parent Project Muscular Dystrophy (PPMD) FoundationminorGTM or Marketing Partner2023 DREAMS Grant recipient — nonprofit patient advocacy organization fighting to end Duchenne by helping those living with the condition lead longer, stronger lives; grant supports work to address disparity in access to care and research opportunities.
• Perkins School for the Blind — Perkins AccessminorImplementation/ SI/ Consulting PartnerDigital accessibility partner conducting user and expert reviews, WCAG 2.1 AA audits, role-based training, ongoing accessibility support and expert standards guidance for entradatx.com.
• EDPO (European Data Protection Office) and EDPO UK LtdminorOthersGDPR / UK GDPR external data protection representatives appointed by Entrada Therapeutics. EDPO is the EU GDPR representative (Brussels, Belgium); EDPO UK Ltd is the UK GDPR representative (London, UK). Available for data subject requests via online forms.
• Boston While Black; Latinos in Bio; Life Science Cares; OUTbio; Women In BiominorGTM or Marketing PartnerCommunity-based partner organizations supporting Entrada's diversity, equity, and inclusion initiatives across Boston, Cambridge, and the biotech sector. Provide community, mentorship, and challenge the status quo.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Sarepta Therapeutics: Sarepta is the leading commercial DMD franchise with approved exon-skipping PMOs (eteplirsen, golodirsen, casimersen) and Elevidys gene therapy. Directly comparable to Entrada as both companies develop exon-skipping oligonucleotide therapies for DMD populations including exons 44, 45, 50, and 51.
• Avidity Biosciences: Avidity's antibody-oligonucleotide conjugate (AOC) platform has reported ~25% dystrophin production in DMD patients, setting the current competitive bar that Entrada's EEV-oligonucleotide approach must beat in the same exon-skipping populations.
• Dyne Therapeutics: Dyne is developing oligonucleotide therapeutics for DMD using its FORCE™ platform targeting muscle. It is a direct competitor in exon-skipping DMD and shares Entrada's focus on muscle-targeted nucleic acid delivery.
• PepGen: PepGen develops conjugated oligonucleotides for DMD and DM1 using its Enhanced Delivery Oligonucleotide (EDO) platform. Directly comparable to Entrada on modality (oligonucleotide) and on overlap in DMD and DM1 indications.
• Solid Biosciences: Solid Biosciences is developing next-generation DMD therapies including SGT-003 (a gene therapy) and oligonucleotide approaches. It competes in the same DMD patient population targeted by Entrada's ENTR-601 series.
• Capricor Therapeutics: Capricor is developing CAP-1002 (cell therapy) and deramiocel for DMD. It is a relevant comparable as a clinical-stage DMD company targeting the same patient population with a different therapeutic modality, competing for the same physician/patient mindshare and capital.

Broad incumbents

• Vertex Pharmaceuticals: Vertex is Entrada's DM1 collaboration partner (VX-670) and a $26M equity holder. Comparable as a strategic partner/incumbent in DM1 and as a broader rare disease biopharma that could acquire Entrada or expand the relationship.
• Ionis Pharmaceuticals: Ionis is the established antisense oligonucleotide platform company with multiple approved products (e.g., Spinraza for SMA). Comparable to Entrada on oligonucleotide modality and antisense approach, and as a potential acquirer of intracellular delivery technology.
• BioMarin Pharmaceutical: BioMarin is an established rare disease biopharma with prior DMD exposure (Kyndrisa, discontinued) and a broad pipeline in neuromuscular and metabolic indications. Comparable as a larger incumbent that could partner with or acquire Entrada's EEV platform.

Emerging players

• AMO Pharma: AMO Pharma is developing tideglusib for DM1 (Phase 2/3). Relevant emerging competitor in the DM1 indication that Entrada/Vertex's VX-670 also targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@entradatx
• LinkedInlinkedin.com/company/entradatx

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Entrada Therapeutics